ArticleInternational journal of surgery (London, England)2026
Hepatic arterial infusion chemotherapy plus sintilimab as conversion therapy for locally advanced hepatocellular carcinoma: a single-center phase II trial.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with locally advanced hepatocellular carcinoma (aHCC) who have macroscopic vascular invasion typically have a poor prognosis. As the understanding of interventional therapy evolves, the conversion therapy strategy based on interventional approaches can significantly enhance objective response and raise the chance of resection for these patients. While the long-term outcomes of the conversion-to-surgery strategy remain unclear. In this article, we report the results of a phase II clinical trial that focused on the survival benefits and safety of conversion-to-surgery therapy, utilizing hepatic arterial infusion chemotherapy of infusion fluorouracil, leucovorin, and oxaliplatin (FOLFOX-HAIC) combined with sintilimab for locally aHCC.
methodsThis open-label, single-center, two-cohort phase II study recruited a total of 40 patients who had initially unresectable HCC within SYSUCC criteria between March 2019 and July 2020. Patients received FOLFOX-HAIC, combined with intravenous sintilimab (cohort A, N = 30) or not (cohort B, N = 10) every 3 weeks for up to eight courses. Patients who achieved tumor shrinkage and were eligible for surgery received radical resection or ablation, then received sintilimab monotherapy up to 16 doses in total (cohort A) or supportive care (cohort B). The primary endpoint was progression-free survival (PFS) assessed with the Response Evaluation Criteria in Solid Tumors version 1.1.
resultsOf the total 40 subjects, the median age was 50 years (range, 29-70 years). With a median follow-up of 52.9 months (range, 6.6-68.6 months). The median PFS was 19.8 months [95% confidence interval (95% CI), 8.2 months-not reached (NR)] in cohort A, and 17.6 months (95% CI, 4.13 months-NR) in cohort B. The conversion rate was beyond 70% in both cohorts. Of the 26 patients (19 in cohort A and 7 in cohort B) who received liver resection, 4 of cohort A (21%) and 1 of cohort B (14%) achieved pathological complete response. The 5-year overall survival rate of the whole study population was 56.3% (95% CI, 43-74%).
conclusionsHepatic arterial infusion chemotherapy plus sintilimab exhibited impressive outcomes and safety as a conversion therapy for locally aHCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.